From Product Value to Pathway Impact
The NHS Cardiovascular Disease Modern Service Framework is poised to reshape expectations of the pharmaceutical industry. While medicines remain fundamental to improving outcomes, future success may increasingly be defined by how effectively organisations support pathway transformation, reduce inequalities and help systems deliver measurable results.
In her latest Pharmafile article, Visions4Health’s very own Managing Director – Sabina Syed – together with co-author Ewan Maule, explore the implications of the Framework for life sciences organisations and examine why the focus is shifting from product value to pathway impact.
The article provides several strategic yet practical insights into how pharmaceutical companies should demonstrate value beyond the medicine itself, how they can strengthen stakeholder engagement, and how they can become implementation partners in delivering NHS priorities.
